Home > Boards > US Listed > Medical - Drugs > Precipio Inc. (PRPO)

Great call right after you posted that news

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stock1ace1 Member Profile
Member Level 
Followed By 238
Posts 29,631
Boards Moderated 2
Alias Born 04/05/12
160x600 placeholder
Precipio launches up to $20M ATM financing arrangement Seeking Alpha - 4/5/2021 9:53:04 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/2/2021 2:01:14 PM
Precipio reports FY results Seeking Alpha - 3/30/2021 10:26:01 AM
Precipio Announces 95% Annual Growth YoY and 180% Quarterly Growth YoY GlobeNewswire Inc. - 3/30/2021 9:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/29/2021 4:31:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/18/2021 5:31:14 PM
Precipio Announces Q4-2020 and year-end Shareholder Update Call GlobeNewswire Inc. - 3/18/2021 4:30:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/4/2021 3:07:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/3/2021 4:31:18 PM
Mr. Ron Andrews joins Precipio’s Board of Directors GlobeNewswire Inc. - 3/3/2021 1:00:00 PM
Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors GlobeNewswire Inc. - 3/3/2021 11:00:00 AM
Precipio Launches COVID-19 Antibody Testing at Point-of-Care GlobeNewswire Inc. - 1/28/2021 9:30:00 AM
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups GlobeNewswire Inc. - 1/20/2021 10:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:35:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:35:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:35:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:35:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:34:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:34:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:33:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:33:50 PM
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor GlobeNewswire Inc. - 12/10/2020 10:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/3/2020 4:32:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/3/2020 4:32:14 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2020 4:04:53 PM
stock1ace1 Member Level  Wednesday, 10/09/19 11:00:01 PM
Re: MonstaGains post# 3281
Post # of 3536 
Great call right after you posted that news came on 9/30. 1st customer with re-occurring revenue yearly 750k with possible 50 more companies read last line of news on 9/30


First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™

Source: GlobeNewswire Inc.

Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as its molecular testing assay for hematologic malignancies such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPD). TN Oncology’s laboratory has validated the test and will be performing the HemeScreen assay as a lab developed test (LDT) within their laboratory.
This marks the first substantial customer for one of Precipio’s technologies. A first order has been placed - and delivered.

Tennessee Oncology is one of the nation’s largest community-based cancer care specialists. With 90 physicians in 40 locations, Tennessee Oncology deploys a POL (Physician Office Laboratory) which services their physicians. The laboratory runs a full suite of diagnostic services; with the addition of HemeScreen, it is able to provide better turnaround time and a higher quality of service to its physicians.

Tennessee Oncology is part of OneOncology, a partnership of independent community oncology practices working together to deliver comprehensive cancer care that includes the West Cancer Center and New York Cancer and Blood Specialists. Combined, OneOncology has more than 200 oncology providers.

*******~>>>
Based on current volume within Tennessee Oncology’s laboratory, and taking into consideration the affiliate practices within OneOncology, Precipio anticipates revenues of approximately $750,000 per year from this group alone, scaling up beginning in Q4-2019. Furthermore, we estimate that in the US there are likely over 50 similar-size potential customers such as Tennessee Oncology for Precipio’s HemeScreen assay <~~~~********

D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences